Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Keros Therapeutics (KROS) Change in Account Payables: 2019-2024

Historic Change in Account Payables for Keros Therapeutics (KROS) over the last 6 years, with Dec 2024 value amounting to -$249,000.

  • Keros Therapeutics' Change in Account Payables fell 85.62% to -$3.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$2.6 million, marking a year-over-year decrease of 338.69%. This contributed to the annual value of -$249,000 for FY2024, which is 115.43% down from last year.
  • Latest data reveals that Keros Therapeutics reported Change in Account Payables of -$249,000 as of FY2024, which was down 115.43% from $1.6 million recorded in FY2023.
  • In the past 5 years, Keros Therapeutics' Change in Account Payables registered a high of $1.6 million during FY2023, and its lowest value of -$408,000 during FY2022.
  • Over the past 3 years, Keros Therapeutics' median Change in Account Payables value was -$249,000 (recorded in 2024), while the average stood at $319,000.
  • In the last 5 years, Keros Therapeutics' Change in Account Payables spiked by 2,334.43% in 2021 and then plummeted by 127.47% in 2022.
  • Keros Therapeutics' Change in Account Payables (Yearly) stood at $61,000 in 2020, then skyrocketed by 2,334.43% to $1.5 million in 2021, then slumped by 127.47% to -$408,000 in 2022, then spiked by 495.59% to $1.6 million in 2023, then tumbled by 115.43% to -$249,000 in 2024.